Skip to main content
BRISTOL MYERS SQUIBB CO logo

BRISTOL MYERS SQUIBB CO — Investor Relations & Filings

Ticker · BMY ISIN · US1101222073 LEI · HLYYNH7UQUORYSJQCN42 US Manufacturing
Open in API
Filings indexed 3,441 across all filing types
Latest filing 2025-11-03 Capital/Financing Update
Country US United States of America
Listing US BMY

About BRISTOL MYERS SQUIBB CO

https://www.bms.com

Bristol Myers Squibb is a global biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, and commercialization of innovative medicines. The company focuses on addressing serious diseases with significant unmet medical needs, with core therapeutic areas in oncology, immunology, and cardiovascular disease. Its operations encompass the entire product lifecycle, from scientific research and clinical trials to the global distribution and sale of its biopharmaceutical products. The company's mission is to help patients prevail over serious diseases through scientific innovation.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Bristol-Myers Squibb Company. The key content is an announcement of the commencement of cash tender offers to purchase certain outstanding notes, with details about the offer terms referenced in an Offer to Purchase document. The document includes a press release as an exhibit and explicitly states it is not an offer to purchase or solicitation but an announcement of the tender offer commencement. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through tender offers on debt securities. The document length is 4223 characters, which is sufficient for a substantive announcement rather than a brief notice. Therefore, the classification is CAP with high confidence.
2025-11-03 English
424B2
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(2) related to a debt securities offering by BMS Ireland Capital Funding Designated Activity Company, guaranteed by Bristol-Myers Squibb Company. It includes detailed information about the notes being offered, interest rates, maturity dates, underwriting, use of proceeds, risk factors, and other offering details. The document is a formal offering prospectus supplement and accompanying prospectus, which are typical for capital raising activities. It is not a financial report, earnings release, management discussion, or regulatory filing unrelated to financing. The presence of detailed terms of the notes, underwriting information, and use of proceeds clearly indicates this is a Capital/Financing Update document. The document length is substantial (15,000 characters), and it contains the full offering details, not just an announcement or summary, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the correct classification is Capital/Financing Update (CAP).
2025-11-03 English
POSASR
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Registration Statement on Form S-3 filed with the SEC by Bristol-Myers Squibb Company. It includes detailed information about securities offerings, including debt securities, preferred stock, common stock, and warrants. The document is a registration statement amendment related to securities offerings and capital raising activities. It is not a financial report, earnings release, or management discussion. The presence of terms like 'registration statement,' 'prospectus,' and 'offering of securities' clearly indicates this is related to capital and financing updates. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed substantive content, not just an announcement or certification, supporting a high confidence level.
2025-10-31 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-31 English
10-Q
Interim / Quarterly Report Q3 2025
2025-10-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions that the company issued an Earnings Press Release and a Presentation on its website announcing financial results for the third quarter of 2025. The document includes the press release and presentation as exhibits but does not contain the full financial statements or detailed financial analysis itself. The document is relatively short (5797 characters) and serves to furnish the earnings release and presentation rather than being the earnings release itself. According to the rules, such a filing is best classified as a Regulatory Filing (RNS) because it is a current report announcing the earnings release and presentation, not the earnings release document itself or a full interim report. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2025-10-30 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.